23:03 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other...
23:02 , Jun 27, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts LRFN2 -knockout mice could be use to screen autism therapies. Genetic association studies in 324 autism patients, 1,818 schizophrenia patients and 2,120 healthy volunteers identified an association between autism and a...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

Dermacyn Wound regulatory update

Oculus said the British Standards Institution (BSI) and the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved CE Mark reclassification of its Dermacyn wound care product to a Class III medical device from a...
08:00 , Jan 25, 2010 |  BC Week In Review  |  Financial News

GlobeImmune completes venture financing

GlobeImmune Inc. , Louisville, Colo.   Business: Infectious, Cancer   Date completed: 1/19/10   Type: Venture financing   Raised: $17.5 million   Investors: Generali Financial Holding; BSI; existing investors  ...
02:32 , Jan 20, 2010 |  BC Extra  |  Financial News

GlobeImmune raises $17.5 million

GlobeImmune Inc. (Louisville, Colo.) raised $17.5 million in a series E round led by new investors Generali Financial Holding and BSI. Existing investors also participated. GlobeImmune develops targeted molecular immunogens, dubbed Tarmogens, which are recombinant...
07:00 , Oct 20, 2008 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Telormedix S.A. Lugano-Bioggio, Switzerland Technology: Immunological gradient approach to immunomodulators Disease focus: Cancer, autoimmune, infectious Clinical status: Preclinical Founded: 2007 by Lorenzo Leoni, Dennis Carson, Roberto Maj and Rolf Zinkernagel University collaborators: University of California...
07:00 , Oct 20, 2008 |  BioCentury  |  Emerging Company Profile

Telormedix: Riding the gradient

Telormedix S.A. thinks it has found a way to avoid the systemic toxicity that has dashed hopes for some compounds targeting toll-like receptors. By using what it calls an "immunological gradient" approach to drug development,...
02:00 , Oct 1, 2008 |  BC Extra  |  Financial News

Telormedix raises $19 million

Cancer and immune company Telormedix (Lugano-Bioggio, Switzerland) raised CHF21 million ($19 million) in a series A round led by Aravis Venture. Other investors included ProQuest Investments; BSI; Nextech Venture; and Generali Insurance Group. Telormedix's lead...
00:12 , Aug 15, 2008 |  BC Extra  |  Financial News

Speciality European raises EUR 15M

Speciality European Pharma (London, U.K.) raised EUR 15 million ($22.6 million) in a series B round led by BSI. Advent Venture Partners, SEP's founding investor, and Merifin also participated. SEP said it will use the...
07:00 , Apr 10, 2006 |  BioCentury  |  Product Development

CF Foundation collaborations

CF Foundation collaborations The Cystic Fibrosis Foundation has invested in a wide variety of early-stage research activities by biotechs, including discovery tools, target identification studies and the development of specific therapeutics. Last month, the foundation...